Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Avelumab + Platinum Doublet in NSCLC
NCT03480230Phase 2Unknown
- Sponsor
- Arafat Tfayli
- Start
- Jun 2018
- Primary completion
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of avelumab in non-small cell lung cancer (NSCLC), sponsored by Arafat Tfayli. Status: unknown.
02
Drugs
avelumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03480230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480230.